The p53 pathway is targeted for inactivation in most human cancers either directly or indirectly, highlighting its critical function as a tumor suppressor gene. p53 is normally activated by cellular stress and mediates a growth-suppressive response that involves cell cycle arrest and apoptosis. In the case of cell cycle arrest, p21 appears sufficient to block cell cycle progression out of G1 until repair has occurred or the cellular stress has been resolved. The p53-dependent apoptotic response is more complex and involves transcriptional activation of multiple proapoptotic target genes, tissue, and signal specificity, as well as additional events that are less well understood. In this chapter, we summarize the apoptosis pathway regulated by p53 and include some open questions in this field.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
References
Arakawa, H. (2004). Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer 4, 978–987.
Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 2000 14:704–18.
Bennett, M., Macdonald, K., Chan, S. W., Luzio, J. P., Simari, R., and Weissberg, P. (1998). Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282, 290–293.
Bode, A. M. and Dong, Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4, 793–805.
Bredesen, D. E., Mehlen, P., and Rabizadeh, S. (2004). Apoptosis and dependence receptors: a molecular basis for cellular addiction. Physiol Rev 84, 411–430.
Burns, T. F., Bernhard, E. J., and El-Deiry, W. S. (2001). specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 20, 4601–4612.
Burns, T. F., Fei, P., Scata, K. A., Dicker, D. T., and El-Deiry, W. S. (2003). Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23, 5556–5571.
Bykov, V. J., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., and Selivanova, G. (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8, 282–288.
Bykov, V. J., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., and Wiman, K. G. (2005). PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24, 3484–3491.
Cartron, P. F., Gallenne, T., Bougras, G., Gautier, F., Manero, F., Vusio, P., Meflah, K., Vallette, F. M., and Juin, P. (2004). The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 16, 807–818.
Chan, H., Bartos, D. P., and Owen-Schaub, L. B. (1999). Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50–p65 recruitment. Mol Cell Biol 19, 2098–2108.
Chipuk, J. E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D. D., and Green, D. R. (2005). PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309, 1732–1735.
Danial, N. N. and Korsmeyer, S. J. (2004). Cell death: critical control points. Cell 116, 205–219.
Dechant, M. J., Fellenberg, J., Scheuerpflug, C. G., Ewerbeck, V., and Debatin, K. M. (2004). Mutation analysis of the apoptotic “death-receptors” and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer 109, 661–667.
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C. P., DuBose, R. F., Goodwin, R. G., and Smith, C. A. (1997a). Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186, 1165–1170.
Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., and Goodwin, R. G. (1997b). The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7, 813–820.
El-Deiry, W. S. (2003). The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22, 7486–7495.
Essmann, F., Pohlmann, S., Gillissen, B., Daniel, P, T., Schulze,-Osthoff. K., and Janicke, R. U. (2005). Irradiation-induced translocation of p53 to mitochondria in the absence of apoptosis. J Biol Chem 280, 37169–37177.
Fei, P., Wang, W., Kim, S. H., Wang, S., Burns, T. F., Sax, J. K., Buzzai, M., Dicker, D. T., McKenna, W. G., Bernhard, E. J., and El-Deiry, W. S. (2004). Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 6, 597–609.
Fei, P., Bernhard, E. J., and El-Deiry, W. S. (2005). Tissue-specific induction of p53 targets in vivo. Cancer Res 62, 7316–7327.
Finnberg, N., Gruber, J. J., Fei, P., Rudolph, D., Bric, A., Kim, S. H., Burns, T. F., Ajuha, H., Page, R., Wu, G. S., Chen, Y., McKenna, W. G., Bernhard, E., Lowe, S., Mak, T., and El-Deiry, W. S. (2005). DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 25, 2000–2013.
Fisher, M. J., Virmani, A. K., Wu, L., Aplenc, R., Harper, J. C., Powell, S. M., Rebbeck, T. R., Sidransky, D., Gazdar, A. F., and El-Deiry, W. S. (2001). Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7, 1688–1697.
Foster, B. A., Coffey, H. A., Morin, M. J., and Rastinejad, F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510.
Fuchs, E. J., McKenna, K. A., Bedi, A. (1997). p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. Cancer Res 57, 2550–2554.
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88–91.
Gupta, S., Radha, V., Furukawa, Y., and Swarup, G. (2001). Direct transcriptional activation of human caspase-1 by tumor suppressor p53. J Biol Chem 276, 10585–10588.
Han, J., Flemington, C., Houghton, A. B., Gu, Z., Zambetti, G. P, Lutz, R. J., Zhu, L., and Chittenden, T. (2001). Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 98, 11318–11323.
Harris, A. L. (2002). Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38–47.
Ho, C. K., Bush, J. A., and Li, G. (2003). Tissue-specific regulation of Apaf-1 expression by p53. Oncol Rep 10, 1139–1143.
Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., and Murphy, M. (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277, 3247–3257.
Ichwan, S. J., Yamada, S., Sumrejkanchanakij, P., Ibrahim-Auerkari, E., Eto, K., and Ikeda, M. A. (2006). Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells. Oncogene 25, 1216–1224.
Hupp, T. R, Sparks, A., and Lane, D. P. (1995). Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83, 237–245.
Ihrie, R. A., Marques, M. R., Nguyen, B. T., Horner, J. S., Papazoglu, C., Bronson, R. T., Mills, A. A., and Attardi, L. D. (2005). Perp is a p63-regulated gene essential for epithelial integrity. Cell 120, 843–856.
Ihrie, R. A., Bronson, R. T., and Attardi, L. D. (2006). Adult mice lacking the p53/p63 target gene Perp are not predisposed to spontaneous tumorigenesis but display features of ectodermal dysplasia syndromes. Cell Death Differ 13(9), 1614–1618.
Ito, A., Lai, C. H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., and Yao, T. P. (2001). p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20, 1331–1340.
Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K. H., Han, J., Chittenden, T., Ihle, J. N., McKinnon, P. J., Cleveland, J. L., and Zambetti, G. P. (2003). Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321–328.
Jin, Y., Zeng, S. X., Lee, H., and Lu, H. (2004). MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J Biol Chem 279, 20035–20043.
Kamer, I., Sarig, R., Zaltsman, Y., Niv, H., Oberkovitz, G., Regev, L., Haimovich, G., Lerenthal, Y., Marcellus, R. C., and Gross, A. (2005). Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 122, 593–603.
Kim, K., Fisher, M. J, Xu, S. Q., and El-Deiry, W. S. (2000). Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6, 335–346.
Lamhamedi-Cherradi, S. E., Zheng, S. J., Maguschak, K. A., Peschon, J., and Chen, Y. H. (2003). Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 4, 255–260.
Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y., Lowe, S. W., Kastan, M., and Giaccia, A. (2001). Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21, 1297–1310.
LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J, Schow, P., Fong, S., Schwall, R., Sinicropi, D., and Ashkenazi, A. (2002). Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8, 274–281.
Lee, S. H., Shin, M. S., Kim, H. S., Lee, H. K., Park, W. S., Kim, S. Y., Lee, J. H., Han, S. Y., Park, J. Y., Oh, R. R., Kang, C. S., Kim, K. M., Jang, J. J., Nam, S. W., Lee, J. Y., and Yoo, N. J. (2001). Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin’s lymphoma. Oncogene 20, 399–403.
Lehar, S. M., Nacht, M., Jacks, T., Vater, C. A., Chittenden, T., and Guild, B. C. (1996). Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells. Oncogene 12, 1181–1187.
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., and Korsmeyer, S. J. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183–192.
Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E., and George. D. L. (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6, 443–450.
Lindsten, T., Ross, A. J., King, A., Zong, W. X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., Chen, Y., Wei, M., Eng, V. M., Adelman, D. M., Simon, M. C., Ma, A., Golden, J. A., Evan, G., Korsmeyer, S. J., MacGregor, G. R., and Thompson, C. B. (2000). The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6, 1389–1399.
Liu, Q., El-Deiry, W. S., and Gazitt, Y. (2005). Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp Hematol 29, 962–970.
Liu, X., Yue, P., Khuri, F. R., and Sun, S. Y. (2004). p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64, 5078–5083.
Liu, X., Yue, P., Khuri, F. R., and Sun, S. Y. (2005). Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 65, 9169–9175.
Longley, D. B., Allen, W. L., McDermott, U., Wilson, T. R., Latif, T., Boyer, J., Lynch, M., and Johnston, P. G. (2004). The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clin Cancer Res 10, 3562–3571.
Lowe, S. W. and Sherr, C. J. (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13, 77–83.
MacLachlan, T. K. and El-Deiry, W. S. (2002). Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci USA 99, 9492–9497.
Medema, J. P, Scaffidi, C., Kischkel, F. C., Shevchenko, A., Mann M, Krammer, P. H, and Peter, M. E. (1997). FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 16, 2794–2804.
Meng, R. D., McDonald, E. R. III, Sheikh, M. S., Fornace, A. J., Jr., and El-Deiry, W. S. (2000). The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 1, 130–144.
Michael, D. and Oren, M. (2003). The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13, 49–58.
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., and Moll, U. M. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11, 577–590.
Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., and Krammer, P. H. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188, 2033–2045.
Miyashita, T. and Reed, J. C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293–299.
Moroni, M. C., Hickman, E. S., Lazzerini Denchi, E., Caprara, G., Colli, E., Cecconi, F., Muller, H., and Helin, K. (2001). Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3, 552–558.
Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S. L., Ng, SL., and Fesik, S. W. (1996). X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335–341.
Munsch, D., Watanabe-Fukunaga, R., Bourdon, J. C., Nagata, S., May, E., Yonish-Rouach, E., and Reisdorf, P. (2000). Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis. J Biol Chem 275, 3867–3872.
Murphy, M., Ahn, J., Walker, K. K., Hoffman, W. H., Evans, R. M., Levine, A. J., and George, D. L. (1999). Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13, 2490–2501.
Nagata, S. (1999). Fas ligand-induced apoptosis. Annu Rev Genet. 33:29–55.
Nakano, K. and Vousden, K. (2001). H. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7, 683–694.
O’Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57, 4285–4300.
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. (2000a). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053–1058.
Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., and Taya, Y. (2000b). p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849–862.
Okamura, S., Arakawa, H., Tanaka, T., Nakanishi, H., Ng, C. C., Taya, Y., Monden, M., Nakamura, Y. (2001). p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol. Cell. 8, 85–94.
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., et al. (1995). Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15, 3032–3040.
Ozoren, N. and El-Deiry, W. S. (2003). Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol 13, 135–1347.
Ozoren, N., Fisher, M. J., Kim, K., Liu, C. X., Genin, A., Shifman, Y., Dicker, D. T., Spinner, N. B., Lisitsyn, N. A., and El-Deiry, W. S. (2000). Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 16, 917–925.
Pai, S. I., Wu, G. S., Ozoren, N., Wu, L., Jen, J., Sidransky, D., and El-Deiry, W. S. (1998). Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58, 3513–3518.
Pan, G., O’Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. (1997a). The receptor for the cytotoxic ligand TRAIL. Science 276, 111–113.
Pan, G., Ni, J., Wei, Y. F., Yu, G., Gentz, R., and Dixit, V. M. (1997b). An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815–818.
Riedl, S. J. and Shi, Y. (2004). Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5, 897–907.
Pearson, A. S., Spitz, F. R., Swisher, S. G., Kataoka, M., Sarkiss, M. G., Meyn, R. E., McDonnell, T. J., Cristiano, R. J., and Roth, J. A. (2000). Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells. Clin Cancer Res 6, 887–890.
Pohl, U., Wagenknecht, B., Naumann, U., and Weller, M. (1999). p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis. Cell Physiol Biochem 9, 29–37.
Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W., Vogelstein, B. (1997). A model for p53-induced poptosis. Nature. 389:300–5.
Rocco, J. W., Leong, C. O., Kuperwasser, N., DeYoung, M. P., and Ellisen, L. W. (2006). p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9, 45–56.
Rodriguez, M. S., Desterro, J. M., Lain, S., Lane, D. P., and Hay, R. T. (2000). Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 20, 8458–8467.
Roy, S., Packman, K., Jeffrey, R., and Tenniswood, M. (2005). Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12, 482–491.
Ruiz de Almodovar, C., Ruiz-Ruiz, C., Rodriguez, A., Ortiz-Ferron, G., Redondo, J. M., and Lopez-Rivas, A. (2004). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. J Biol Chem 279, 4093–4101.
Ryan, A. E., Shanahan, F., O’Connell, J., and Houston, A. M. (2005). Addressing the “Fas counterattack” controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 65, 9817–9823.
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., Thompson, C. B., and Fesik, S. W. (1997). Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986.
Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., and El-Deiry, W. S. (2002). BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4, 842–849.
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17, 1675–1687.
Sheikh, M. S., Huang, Y., Fernandez-Salas, E. A., El-Deiry, W. S., Friess, H., Amundson, S., Yin, J., Meltzer, S. J., Holbrook, N. J., and Fornace, A. J., Jr. (1999). The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 18, 4153–4159.
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818–821.
Shetty, S., Graham, B. A., Brown, J. G., Hu, X., Vegh-Yarema, N., Harding, G., Paul, J. T., and Gibson, S. B. (2005). Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 25, 5404–5416.
Shibue, T., Takeda, K., Oda, E., Tanaka, H., Murasawa, H., Takaoka, A., Morishita, Y., Akira, S., Taniguchi, T., and Tanaka, N. (2003). Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 17, 2233–2238.
Shin, M. S., Kim, H. S., Lee, S. H., Park, W. S., Kim, S. Y., Park, J. Y., Lee, J. H., Lee, S. K., Lee, S. N., Jung. S. S., Han, J. Y., Kim, H., Lee, J. Y., and Yoo, N. J. (2001). Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 61, 4942–4946.
Snyder, E. L., Meade, B. R., Saenz, C. C., and Dowdy, S. F. (2004). Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol E36.
Soengas, M. S., Alarcon, R. M., Yoshida, H., Giaccia, A. J., Hakem, R., Mak, T. W., and Lowe, S. W. (1999). Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284, 156–159.
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., Cordon-Cardo, C., and Lowe, S. W. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207–211.
Sun, Y. and Leaman, D. W. (2005). Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. J Biol Chem 280(16), 15561–15568.
Takimoto, R. and El-Deiry, W. S. (2000). Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19, 1735–1743.
Takimoto, R., Wang, W., Dicker, D. T., Rastinejad, F., Lyssikatos, J., and El-Deiry, W. S. (2002). The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1, 47–55.
Takimoto, R., Kato, J., Terui, T., Takada, K., Kuroiwa, G., Wu, J., Ohnuma, H., Takahari, D., Kobune, M., Sato, Y., Takayama, T., Matsunaga, T., and Niitsu, Y. (2005). Augmentation of Antitumor Effects of p53 Gene Therapy by Combination with HDAC Inhibitor. Cancer Biol. Ther. 4, 421–428.
Tanikawa, C., Matsuda, K., Fukuda, S., Nakamura, Y., and Arakawa, H. (2003). p53RDL1 regulates p53-dependent apoptosis. Nat Cell Biol 5, 216–222.
Thiery, J., Abouzahr, S., Dorothee, G., Jalil, A., Richon, C., Vergnon, I., Mami-Chouaib, F., and Chouaib, S. (2005). p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways. J Immunol 174, 871–878.
Terui, T., Murakami, K., Takimoto, R., Takahashi, M., Takada, K., Murakami, T., Minami, S., Matsunaga, T., Takayama, T., Kato, J., and Niitsu, Y. (2003). Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 63, 8948–8954.
Tomita, Y., Marchenko, N., Erster, S., Nemajerova, A., Dehner, A, Klein, C., Pan, H., Kessler, H., Pancoska, P., and Moll, U. M. (2006). WTp53 but not tumor-derived mutants bind to BCL2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 281, 8600.
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., Myklebost, O., Heimbrook, D. C., and Vassilev, L. T. (2006). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci USA 103, 1888–1893.
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848.
Villunger, A., Michalak, E. M., Coultas, L., Mullauer, F., Bock, G., Ausserlechner, M. J., Adams, J. M., and Strasser, A. (2003). p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302, 1036–1038.
Vogelstein, B., Lane, D., and Levine, A. J. (2000). Surfing the p53 network. Nature 408, 307–310.
Wang, S. and El-Deiry, W. S. (2003a). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22, 8628–8633.
Wang, S. and El-Deiry, W. S. (2003b). Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 100, 15095–15100.
Wang, S. and El-Deiry, W. S. (2004a). Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64, 6666–7662.
Wang, W. and El-Deiry, W. S. (2004b). Targeting p53 by PTD-mediated transduction. Trends Biotechnol 22, 431–434.
Wang, W., Takimoto, R., Rastinejad, F., and El-Deiry, W. S. (2003). Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 23, 2171–2181.
Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730.
Weinstein, J. N., Myers, T. G., O’Connor, P. M., Friend, S. H., Fornace, A. J. Jr., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Viswanadhan, V. N., Johnson, G. S., Wittes, R. E., and Paull, K. D. (1997). An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343–349.
Wu, G. S., Burns, T. F., McDonald, E. R., III, Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D. D., Zhou, J. Y., Muschel, R., Hamilton, S. R., Spinner, N. B., Markowitz, S., Wu, G., and El-Deiry, W. S. (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17, 141–143.
Wu, W. S., Heinrichs, S., Xu, D., Garrison, S. P., Zambetti, G. P., Adams, J. M., and Look, A. T. (2005). Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123, 641–653.
Wu, Y., Mehew, J. W., Heckman, C. A., Arcinas, M., and Boxer, L. M. (2001). Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20, 240–251.
Xiao, S., Marshak-Rothstein, A., and Ju, S. T. (2001). Sp1 is the major fasl gene activator in abnormal CD4(−) CD8(−) B220(+) T cells of lpr and gld mice. Eur J Immunol 31, 3339–3348.
Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., and Vogelstein, B. (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673–682.
Yu, J., Wang, Z., Kinzler, K. W., Vogelstein, B., and Zhang, L. (2003). PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100, 1931–1936.
Zha, J., Weiler, S., Oh, K. J., Wei, M. C., and Korsmeyer, S. J. (2000). Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 290, 1761–1765.
Zinkel, S. S., Hurov, K. E., Ong, C., Abtahi, F. M., Gross, A., and Korsmeyer, S. J. (2005). A role for proapoptotic BID in the DNA-damage response. Cell 122, 579–591.
Zhao, X., Ayer, R. E., Davis, S. L., Ames, S. J., Florence, B., Torchinsky, C., Liou, J. S., Shen, L., and Spanjaard, R. A. (2005). Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness. Cancer Res 65, 2125–2129.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science + Business Media B.V
About this chapter
Cite this chapter
Kuribayashi, K., El-Deiry, W.S. (2008). Regulation of Programmed Cell Death by the P53 Pathway. In: Programmed Cell Death in Cancer Progression and Therapy. Advances in Experimental Medicine and Biology, vol 615. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6554-5_10
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6554-5_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6553-8
Online ISBN: 978-1-4020-6554-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)